Merck KGaA Investor Presentation — August 2021

Document content

August 5, 2021Q22021 resultsStrong Quarter With

Double -Digit Growth Driven by

Cautionary Note Regarding Forward -Looking Statements andfinancial indicators

This communication may include “forward -looking statements.” Statements that include words such as “anticipate,” “expect,” “shou ld,” “would,” “intend,” “plan,” “project,” “seek,”

“believe,” “will,” and other words of similar meaning in connection with future events or future operating or financial perfo rmance are often used to identify forward -looking statements.

All statements in this communication, other than those relating to historical information or current conditions, are forward -looking statements. We intend these forward -looking

statements to be covered by the safe harbor provisions for forward -looking statements in the Private Securities Litigation Refor m Act of 1995. These forward -looking statements are

subject to a number of risks and uncertainties, many of which are beyond control of Merck KGaA, Darmstadt, Germany, which could cause actual results to differ materially from such

Risks anduncertainties include, butarenotlimited to:therisks ofmore restrictive regulatory requirements regarding drug pricing, reimbursement andapproval ;theriskofstricter

regulations forthemanufacture, testing andmarketing ofproducts ;theriskofdestabilization ofpolitical systems andtheestablishment oftrade barriers ;theriskofachanging

marketing environment formultiple sclerosis products intheEuropean Union ;theriskofgreater competitive pressure duetobiosimilars ;therisks ofresearch anddevelopment ;the

risks ofdiscontinuing development projects andregulatory approval ofdeveloped medicines ;theriskofatemporary banonproducts/production facilities orofnon-registration of

products duetonon-compliance withquality standards ;theriskofanimport banonproducts totheUnited States duetoanFDAwarning letter ;therisks ofdependency onsuppliers ;